Read about news from Cardinal Analytx Solutions, Neuro Rehab VR and UnityPoint Health.

MedCity News caught up with Omron Healthcare CEO Ranndy Kellogg at the the AdvaMed Digital MedTech Conference in San Francisco to speak about the company’s new products, emerging business lines and how collaboration with other companies have driven recent innovation.

Through the integration, patients can launch TytoCare telehealth visits from Epic’s MyChart app. Following the visit, clinical exam data is delivered to the Epic EHR.

The gene therapy will be priced at $2.125 million, or $425,000 per year for five years, under an installment-based payment program for which it is partnered with specialty pharmacy Accredo.

Life sciences companies overwhelmed with large volumes of information and data available – both in terms of therapies and patient-reported outcomes – must establish a more efficient, bi-directional communication model with care teams to succeed.

At the MedCity INVEST Pop Health conference, Virta Health medical director Dr. Sarah Hallberg asked: “What is going to be the most cost-efficient thing — to continue to prescribe medications that we’re all going to bear the cost of (especially in the underserved population) or to give them food … to prevent the disease?”

The product (codenamed Dylan) is being developed by Amazon’s hardware development team Lab126 and its Alexa division. Designed to be worn on the wrist, the device seemingly has a form factor similar to a smartwatch.

Gottlieb previously worked at NEA from 2007 to 2017, when he was appointed as commissioner of the FDA. He stepped down from that role in March, also returning to another previous employer, the American Enterprise Institute.

The regulator is opening up the program to 510(k) submissions, instead of its initial focus on companies moving through the De Novo regulatory pathway.

In an article published in the journal mAbs Monday, executives from Adimab alleged that MIT’s Ram Sasisekharan copied prior monoclonal antibody research. Visterra, a company Sasisekharan founded that had been developing one of the antibodies, was acquired by Otsuka for $430M last year.